METHOTREXATE INJECTION BP SOLUTION
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
30-10-2019
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
METHOTREXATE (METHOTREXATE SODIUM)
Tillgänglig från:
ACCORD HEALTHCARE INC
ATC-kod:
L01BA01
INN (International namn):
METHOTREXATE
Dos:
25MG
Läkemedelsform:
SOLUTION
Sammansättning:
METHOTREXATE (METHOTREXATE SODIUM) 25MG
Administreringssätt:
INTRAVENOUS
Enheter i paketet:
20ML
Receptbelagda typ:
Prescription
Terapiområde:
ANTINEOPLASTIC AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0107545002; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2018-04-12
Produktens egenskaper
Page 1 of 55
_ _
PRODUCT MONOGRAPH
PR
METHOTREXATE INJECTION BP
25 MG / ML METHOTREXATE (AS METHOTREXATE SODIUM)
FORMULATION WITHOUT PRESERVATIVE
PR
METHOTREXATE INJECTION BP
25 MG / ML METHOTREXATE (AS METHOTREXATE SODIUM)
FORMULATION WITH PRESERVATIVE
Sterile Solution
Antimetabolite and Antirheumatic
Accord Healthcare Inc.
3535 boul. St. Charles suite 704
Kirkland, QC, H9H 5B9
Canada
Date of Revision:
October 30, 2019
Control No. 231320
Page 2 of 55
_ _
_Pr_
_Methotrexate Injection BP, Product Monograph, Accord Healthcare Inc.
_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
5
ADVERSE REACTIONS
.......................................................................................................
14
DRUG INTERACTIONS
.......................................................................................................
19
DOSAGE AND ADMINISTRATION
...................................................................................
23
OVERDOSAGE
.....................................................................................................................
34
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 35
STORAGE AND STABILITY
...............................................................................................
37
SPECIAL HANDLING INSTRUCTIONS
............................................................................
38
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 39
PART
Läs hela dokumentet
